European Psychiatry - Volume 33

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

S531

(GAF), Structured Clinical Interview (SCID 1-2), Level of Expressed

Emotion Scale (LEE), Paykel scale, State and Trait Anxiety Inven-

tory (STAY 1-2), State-Trait Anger Expression Inventory (STAXY),

Barratt Impulsiveness Scale (BIS-11).

Results

Levels of anxiety (both state and trait) are higher in the

ED group than in SCHZ. As far as the STAXY is concerned, SCHZ

patients score higher than ED ones on control over anger, while

general index of anger expressionwas higher in ED patients. We did

not find significant differences in EE between two groups, except

for the patient’s emotional response of the patient to the disease,

which was greater among SCHZ. Both SCHZ and ED patients scored

higher on the LEE, Paykel and STAY than their caregivers.

Conclusions

SCHZ and ED patients show different patterns of

anxiety and anger, but similar profile as far as EE is concerned.

Implications for treatment will be discussed.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1551

EV567

Multifactorial ethiopathogenic in

eating disorders

E. Garcia

1 ,

∗

, M. Leon

, F. Polo

Ciudad Real, Spain

Hospital General de Ciudad Real, UTCA, Ciudad Real, Spain

∗

Corresponding author.

Eating Disorders is a heterogeneous group of syndromes which

includes many factors in their develop. The three main syndromes,

AN, BN and EDNOS has been defined in last DSM as indepen-

dent entities. However is well known that a group of patients may

change its presentation along time, so also been at first diagnosed

of AN, lately will fulfil criteria for BN or EDNOS.

In the other hand, if we compare two patients with the same syn-

drome, as BN, or AN

. . .

We may easily find big differences in personality, stressors

. . .

and

in some cases the only common factor is the clinical presentation.

Behind all of this is the fact that syndromic classification drives to

empiric treatments that are far the most validated.

But although there is a well known evolution in this disorders, with

a not so bad income as one could think initially (in some cases one

third could recover without treatment), whatmaywe dowith those

patients that are resistant for empiric treatments?

And it is our opinion that a deeper knowledge of all the factors that

contribute to the syndrome or its presentation, as well as those

related to treatments results, should be taken into account.

We have reviewed all knowledge about these issues and we have

completed it with our clinical practise using a 50 patients data base,

here we will show our results, that are basically that even the same

factors interact in different ways in each patient, so it is not just the

ingredients but the recipe.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1552

EV568

Atypical antipsychotics use in eating

disorders. Review

J.M. Hernández Sánchez

1 ,

∗

, M .F

. Molina López

2 ,

M.C. Cancino Botello

, M.Á. Canseco Navarro

, D. Pe˜na Serrano

Valencia, Spain

Hospital General de Valencia, Psychiatry, Valencia, Spain

∗

Corresponding author.

Introduction

Eating disorders often have serious medical com-

plications, including the highest mortality rates of any psychiatric

disorder. The search for an optimal therapeutic strategy during the

last decades has been difficult and it has included antidepressants,

antipsychotics, anticonvulsants, benzodiazepines and mood sta-

bilisers.

Objectives

To review the medical literature related to the treat-

ment of eating disorders with atypical antipsychotics.

Methods

Medline search and ulterior review of the related liter-

ature. Keywords: “eating disorders”; “anorexia nervosa”; “bulimia

nervosa”; “binge eating disorder”; “antypsychotic agents”.

Results

To the date, most of the studies have been with olan-

zapine. Olanzapine has shown effects, not only on weight gain,

but also on management of other psychological features such as

obsessive-compulsive symptoms, depression, aggression, persis-

tence and interpersonal distrust. However, most of these studies

have been compared to placebo, and binge-eating behaviour has

also been described when using olanzapine (not with aripiprazole

or ziprasidone). Recently, Marzola et al, when comparing olanza-

pine + SSRIs versus aripiprazol + SSRIs, described that aripiprazole

(compared to olanzapine) is significantlymore effective in reducing

purging episodes, eating preoccupations and rituals.

Conclusions

So far, aripiprazol and olanzapine have been proved

to be the most effective atypical antypsichotics in eating disor-

ders, especially in anorexia nervosa. However, most of studies were

placebo-controlled and in quite small samples. Further investiga-

tion is needed.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.